535 related articles for article (PubMed ID: 34070359)
1. New Approaches and Repurposed Antiviral Drugs for the Treatment of the SARS-CoV-2 Infection.
Vittoria BL; Imbesi C; Irene G; Calì G; Bitto A
Pharmaceuticals (Basel); 2021 May; 14(6):. PubMed ID: 34070359
[TBL] [Abstract][Full Text] [Related]
2. Current Strategies of Antiviral Drug Discovery for COVID-19.
Mei M; Tan X
Front Mol Biosci; 2021; 8():671263. PubMed ID: 34055887
[TBL] [Abstract][Full Text] [Related]
3. Potential Therapeutic Targets and Vaccine Development for SARS-CoV-2/COVID-19 Pandemic Management: A Review on the Recent Update.
Anand U; Jakhmola S; Indari O; Jha HC; Chen ZS; Tripathi V; Pérez de la Lastra JM
Front Immunol; 2021; 12():658519. PubMed ID: 34276652
[TBL] [Abstract][Full Text] [Related]
4. An evidence-based systematic review on emerging therapeutic and preventive strategies to treat novel coronavirus (SARS-CoV-2) during an outbreak scenario.
Gudadappanavar AM; Benni J
J Basic Clin Physiol Pharmacol; 2020 Sep; 31(6):. PubMed ID: 32924964
[TBL] [Abstract][Full Text] [Related]
5. Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2) - an update on the status.
Abd El-Aziz TM; Stockand JD
Infect Genet Evol; 2020 Sep; 83():104327. PubMed ID: 32320825
[TBL] [Abstract][Full Text] [Related]
6. Rapid in vitro assays for screening neutralizing antibodies and antivirals against SARS-CoV-2.
Park JG; Oladunni FS; Chiem K; Ye C; Pipenbrink M; Moran T; Walter MR; Kobie J; Martinez-Sobrido L
J Virol Methods; 2021 Jan; 287():113995. PubMed ID: 33068703
[TBL] [Abstract][Full Text] [Related]
7. A critical overview of current progress for COVID-19: development of vaccines, antiviral drugs, and therapeutic antibodies.
Kumari M; Lu RM; Li MC; Huang JL; Hsu FF; Ko SH; Ke FY; Su SC; Liang KH; Yuan JP; Chiang HL; Sun CP; Lee IJ; Li WS; Hsieh HP; Tao MH; Wu HC
J Biomed Sci; 2022 Sep; 29(1):68. PubMed ID: 36096815
[TBL] [Abstract][Full Text] [Related]
8. Approaches and advances in the development of potential therapeutic targets and antiviral agents for the management of SARS-CoV-2 infection.
Krishna G; Pillai VS; Veettil MV
Eur J Pharmacol; 2020 Oct; 885():173450. PubMed ID: 32739174
[TBL] [Abstract][Full Text] [Related]
9. Potential Repurposed Therapeutics and New Vaccines against COVID-19 and Their Clinical Status.
Banday AH; Shameem SA; Ajaz SJ
SLAS Discov; 2020 Dec; 25(10):1097-1107. PubMed ID: 32692266
[TBL] [Abstract][Full Text] [Related]
10. Old Drugs for a New Virus: Repurposed Approaches for Combating COVID-19.
Saul S; Einav S
ACS Infect Dis; 2020 Sep; 6(9):2304-2318. PubMed ID: 32687696
[TBL] [Abstract][Full Text] [Related]
11. Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses.
Artese A; Svicher V; Costa G; Salpini R; Di Maio VC; Alkhatib M; Ambrosio FA; Santoro MM; Assaraf YG; Alcaro S; Ceccherini-Silberstein F
Drug Resist Updat; 2020 Dec; 53():100721. PubMed ID: 33132205
[TBL] [Abstract][Full Text] [Related]
12. An update on COVID-19: SARS-CoV-2 variants, antiviral drugs, and vaccines.
Hillary VE; Ceasar SA
Heliyon; 2023 Mar; 9(3):e13952. PubMed ID: 36855648
[TBL] [Abstract][Full Text] [Related]
13. Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19).
Shanmugaraj B; Siriwattananon K; Wangkanont K; Phoolcharoen W
Asian Pac J Allergy Immunol; 2020 Mar; 38(1):10-18. PubMed ID: 32134278
[TBL] [Abstract][Full Text] [Related]
14. COVID-19 vaccines: their effectiveness against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its emerging variants.
Noor R; Shareen S; Billah M
Bull Natl Res Cent; 2022; 46(1):96. PubMed ID: 35431535
[TBL] [Abstract][Full Text] [Related]
15. Structure-based virtual screening of phytochemicals and repurposing of FDA approved antiviral drugs unravels lead molecules as potential inhibitors of coronavirus 3C-like protease enzyme.
Bahadur Gurung A; Ajmal Ali M; Lee J; Abul Farah M; Mashay Al-Anazi K
J King Saud Univ Sci; 2020 Sep; 32(6):2845-2853. PubMed ID: 32837113
[TBL] [Abstract][Full Text] [Related]
16. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.
Conti P; Caraffa A; Gallenga CE; Kritas SK; Frydas I; Younes A; Di Emidio P; Tetè G; Pregliasco F; Ronconi G
J Biol Regul Homeost Agents; 2021; 35(1):1-4. PubMed ID: 33377359
[TBL] [Abstract][Full Text] [Related]
17. Perspectives on Repurposed Drugs Based on Globally Accepted Therapeutic Guidelines to Combat SARS-CoV-2 Infection.
Rosalia R
Drug Healthc Patient Saf; 2021; 13():11-18. PubMed ID: 33536792
[TBL] [Abstract][Full Text] [Related]
18. Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CL
Froggatt HM; Heaton BE; Heaton NS
J Virol; 2020 Oct; 94(22):. PubMed ID: 32843534
[TBL] [Abstract][Full Text] [Related]
19. An overview of anti-SARS-CoV-2 and anti-inflammatory potential of baicalein and its metabolite baicalin: Insights into molecular mechanisms.
Dinda B; Dinda M; Dinda S; De UC
Eur J Med Chem; 2023 Oct; 258():115629. PubMed ID: 37437351
[TBL] [Abstract][Full Text] [Related]
20. TMPRSS2 and RNA-Dependent RNA Polymerase Are Effective Targets of Therapeutic Intervention for Treatment of COVID-19 Caused by SARS-CoV-2 Variants (B.1.1.7 and B.1.351).
Lee J; Lee J; Kim HJ; Ko M; Jee Y; Kim S
Microbiol Spectr; 2021 Sep; 9(1):e0047221. PubMed ID: 34378968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
